Obesity Trial, Recruiting NCT07236788 Sponsor: China-Japan Friendship Hospital Condition: Obesity
Back to Obesity

Obesity Trial, Recruiting

NCT07236788
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men with a haemoglobin (a measure of red blood cell health) level between 10 and 14 g/dL, or women with a level between 10 and 13 g/dL, at the start of the trial
  • People whose iron levels are low, specifically with a ferritin level (a measure of iron stores) below 100 μg/L and a transferrin saturation level (another iron measure) below 20%
  • People with a Body Mass Index (BMI) above 30 kg/m² (confirm with trial site for how BMI will be measured)

Who may not be able to join:

  • People who have previously had a serious allergic reaction to iron given by injection or drip
  • People whose red blood cells are larger than normal, shown by a mean corpuscular volume (MCV) reading above 100 fL (confirm with trial site)
  • People who have received iron through a drip or injection in the past 3 months
  • People currently being treated for any type of cancer
  • People who have too much iron in their body, or any other blood disorder
  • People with an active infectious disease such as hepatitis B
  • People with moderately to severely reduced liver function, including certain liver conditions or abnormal liver test results
  • People with any ongoing acute or long-term infections, heart failure, or other conditions known to affect how the body processes iron
  • People with stage 3 or more advanced chronic kidney disease, indicated by a kidney filtration rate (eGFR) below 60 ml/min
  • Women who are pregnant or currently breastfeeding
  • People with an active infection, rheumatoid arthritis, or significant joint inflammation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 188 1048 8650

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
China-Japan Friendship Hospital
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

changes in Hb concentration compared to baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov